Meyer Pharmaceuticals Acquires NF-kappaB Decoy Technology For Treatment Of Inflammatory Disease
Meyer Pharmaceuticals LLC announced that it has obtained a license for a new drug technology for the treatment of inflammatory conditions such as arthritis and skin disease. The drug is a patented oligonucleotide (a small segment of DNA) that specifically blocks NF-kB, a transcription factor that activates pro-inflammatory genes. The technology is licensed from AnGes MG, Inc. [click link for full article]